Genmab (CPH:GEN)

QUOTE AND NEWS
FierceBiotech  Mar 19  Comment 
In this week's EuroBiotech Report, Neil Woodford is tightening his ties to Malin, the investment vehicle set up by Kelly Martin and other former Elan executives. A report that Malin could hit the upper end of its range was one of two pieces of...
FierceBiotech  Mar 19  Comment 
Genmab has tweaked its pipeline, picking up assets from iDD Biotech while dropping the option to co-develop HuMax-TAC-ADC with ADC Technologies. The reshuffle leaves Genmab with a new array of assets to advance toward the clinic.
FierceBiotech  Feb 5  Comment 
In this week's EuroBiotech Report, after years of relying heavily on Neil Woodford's checkbook, early-stage British and European biotechs could soon have another big-name investor to tap for cash: Jim Mellon--a man worth around £800 million ($1.2...
FierceBiotech  Feb 4  Comment 
Phase II data from Genmab have ratcheted up expectations for a fast-track approval of its Johnson & Johnson-partnered treatment for double refractory multiple myeloma. Analysts see the data as strong enough to bring the CD38 monoclonal antibody to...
FierceBiotech  Dec 4  Comment 
Genmab reports that its partners at J&J are starting a Phase II study of daratumumab in non-Hodgkin's lymphoma.
newratings.com  Nov 3  Comment 
BASEL (dpa-AFX) - Genmab :Ofatumumab collaboration contract to be transferred from GSK to Novartis Denmark-based biotechnology company Genmab A/S (GNMSF.PK) said that it has entered into an agreement with GlaxoSmithKline (GSK, GSK.L) and Novartis...
newratings.com  Sep 10  Comment 
WASHINGTON (dpa-AFX) - Seattle Genetics Inc (SGEN) and Genmab A/S (GNMSF.PK) on Wednesday entered into an additional antibody-drug conjugate collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive...





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki